Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

A new anticancer agent (LY186641) interferes with creatinine assay

  • 17 Accesses

Summary

The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Grindey GB, Boder GB, Grossman CS, Howbert JJ, Poore G, Shaw WN, Todd GC, Worzalla JF (1987) Further development of diarylsulfonylureas as anticancer drugs. Proc Am Assoc Cancer Res 28: 309

  2. 2.

    Kroll MH, Roach NA, Poe B, Elin RJ (1987) Mechanism of interference with the Jaffé reaction for creatinine. Clin Chem 33: 1127

  3. 3.

    Taylor CW, Alberts DS, Ketchgam MA, Peng YM, Satterlee WG (1988) A phase I and pharmacokinetic study of LY186641 (LY). Abstract 226, Proceedings of the 24th Annual Meeting of the Am Soc Clin Oncology (ASCO), New Orleans, May 22–24, 1988

Download references

Author information

Correspondence to Marc M. Bonnay.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bonnay, M.M., Recondo, G., Gouyette, A.J. et al. A new anticancer agent (LY186641) interferes with creatinine assay. Cancer Chemother. Pharmacol. 23, 119–120 (1989). https://doi.org/10.1007/BF00273530

Download citation

Keywords

  • Clinical Trial
  • Creatinine
  • Cancer Research
  • Anticancer Agent
  • Parent Compound